Abstracts Archive - Page 417 of 2607 - ACR Meeting Abstracts

Abstract Number: 1817 • ACR Convergence 2023
Geographic Variability of Inflammatory Bowel Disease Related Mortality, 1999-2019; CDC WONDER
Saleha Aziz¹, Anum Akhlaq¹, Sana Gurz² and Yousaf Zafar¹, ¹University of Mississippi Medical Center, Jackson, MS, ²University of Nevada, Las Vegas, NV
Background/Purpose: The United States makes a significant contribution to Inflammatory Bowel Disease (IBD) related disease burden worldwide. However, data on geographic variability of IBD related…
Abstract Number: 1754 • ACR Convergence 2023
Novel and Unique Rheumatoid Factors Cross-React with Viral Epitopes in COVID-19
Maya Amjadi¹, Maxwell Parker², Zihao Zheng¹, Alex Robbins¹, Michael Denny¹, Sara McCoy³, Irene Ong¹ and Miriam Shelef¹, ¹University of Wisconsin, Madison, WI, ²University of Wisconsin-Madison, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Middleton, WI
Background/Purpose: Rheumatoid factors (RFs), polyreactive antibodies canonically known to bind two conformational epitopes of IgG, are a hallmark of rheumatoid arthritis but also can arise…
Abstract Number: 1819 • ACR Convergence 2023
Clinical Indications Associated with New Opioid Use for Pain Management in the United Kingdom Using National Primary Care Data
Max Lyon, Carlos Ramirez Medina, Elinor Davies and Meghna Jani, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Prescription opioids for non-cancer pain in the UK have increased considerably over the past two decades, alongside a rise in associated harms. Despite the…
Abstract Number: 1824 • ACR Convergence 2023
Breakthrough COVID-19 and Severity After Vaccination Among Pregnant Persons with Rheumatic Diseases
Anna Sutton¹, Carolyn Hilliard², Qiuyuan Qin³, Alfred Jared Anzalone⁴, Mary Toth⁵, Rena Patel⁶ and Namrata Singh⁷, ¹Department of Epidemiology, University of Washington School of Public Health, Woodinville, WA, ²Department of Internal Medicine SSM Saint Louis University, St. Louis, MO, ³Department of Public Health, University of Rochester, Rochester, NY, ⁴Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, ⁵Nemours Foundation, Orlando, FL, ⁶Departments of Medicine and Global Health, University of Washington, Seattle, WA, ⁷University of Washington, Bellevue, WA
Background/Purpose: Acknowledgment: Contributed on behalf of the National COVID Cohort Collaborative (N3C) ConsortiumIndividuals with rheumatologic diseases (RD) are at higher risk for severe COVID-19 compared…
Abstract Number: 1823 • ACR Convergence 2023
Higher Body Mass Index and Older Age, Both of Which Are Linked to Immunothrombosis Are Associated with Improved Survival with Baricitinib Therapy in COVID-19 Pneumonia
Paula David¹, Niv Ben-Shabbat², Or Hen¹, Howard Amital³, Abdulla watad⁴ and Dennis McGonagle⁵, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, ²Department of Medicine 'B'. Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ³Sheba Medical Center - Tel Hashomer, Ramat Gan, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Immunothrombosis is a critical pathological feature of fulminant COVID-19 pneumonia in which immunosuppression with common immunomodulatory agents such as corticosteroids, IL-6 receptor blockers, and…
Abstract Number: 1756 • ACR Convergence 2023
Circulating CD4+CD25+CD127-FoxP3+CD39+ T Cells Predict the Response to Methotrexate Across Basal Disease Activity Strata in Early Rheumatoid Arthritis
Maria-Eugenia Miranda-Carus¹, Beatriz Nieto-Carvalhal¹, Alejandro Villalba², Laura Nuño¹, Marta Benito-Miguel³, Marta Novella-Navarro⁴, Irene Monjo⁵, Diana Peiteado¹, Sara García-Carazo¹ and Alejandro Balsa⁴, ¹Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ²Rheumatology Department, La Paz University Hospital, Madrid, Spain, ³Universidad Nebrija, Physiology, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵University Hospital La Paz, Madrid, Spain
Background/Purpose: A subset of human FoxP3+ regulatory T (Treg) cells expresses CD39 (Treg39+) and hydrolyses proinflammatory adenine nucleotides released at inflammatory foci, rendering the antiinflamatory…
Abstract Number: 1760 • ACR Convergence 2023
Methotrexate Augments the Release of Granulocyte-macrophage Colony-stimulating Factor from Activated Rheumatoid Arthritis Fibroblast-like Synoviocytes – Possible Consequences for Persistence of Joint Inflammation
Beatrice Bergström¹, Tilia Selldén¹, Miriam Bollmann², Mattias N.D Svensson¹ and Anna-Karin Hultgård Ekwall³, ¹University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³University of Gothenburg, Kullavik, Sweden
Background/Purpose: Activated fibroblast-like synoviocytes (FLS) are important mediators of synovitis and structural damage in rheumatoid arthritis (RA)[1]. Granulocyte-macrophage colony-stimulating factor (GM-CSF, encoded by the CSF2…
Abstract Number: 1722 • ACR Convergence 2023
Fate-mapping of Synovial Monocytes and Macrophages
Yidan Wang¹, Carla Cuda¹, Deborah Winter² and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Skokie, IL
Background/Purpose: Synovial monocytes and macrophages are heterogenous populations. These populations play diverse roles in the development of arthritis in humans and mice. In recent years,…
Abstract Number: 1820 • ACR Convergence 2023
Statewide Burden of Osteoarthritis in United States Between 1990-2019: A Systematic and Comparative Benchmarking Study
Dhruvkumar Gadhiya¹, Utsav Patel², Hiren Chhayani³, Krushi Shah³, Sneh Patel³, Victor Adedara⁴, Divya Patel³, Hardik Desai⁵ and Swetha Chittipolu⁶, ¹St.Luke's University Health, Anderson Campus, Easton, PA, ²Tulane University, New Orleans, LA, ³G.M.E.R.S. Medical College, Gandhinagar, Gandhinagar, India, ⁴St George’s University SOM, True Blue Greneda, True Blue, Grenada, ⁵Gujarat Adani Institute of Medical Sciences, Bhuj, India., Bhuj, India, ⁶North Mississippi Medical Center, Tupelo, MS
Background/Purpose: Osteoarthritis (OA) is a prevalent and debilitating musculoskeletal condition that has imposed a significant burden on the United States (US) healthcare system. This study…
Abstract Number: 1764 • ACR Convergence 2023
Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease
Breanna Butler¹, Jill Poole¹, Michael Duryee¹, Nozima Aripova¹, Carlos Hunter¹, Bridget Kramer¹, James O'Dell¹, Geoffrey Thiele¹, Bryant England¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Interstitial lung disease (ILD) causes significant complications and mortality in patients with rheumatoid arthritis (RA). We have previously shown that patients with RA-ILD had…
Abstract Number: 1636 • ACR Convergence 2023
Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study
E. William St. Clair¹, Liangwei Wang², Ilias Alevizos², William A. Rees², Alan Baer³, Wan-Fai Ng⁴, Ghaith Noaiseh⁵ and Chiara Baldini⁶, ¹Duke University Medical Center, Durham, NC, ²Horizon Therapeutics, Rockville, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁵University of Kansas Medical Center, Kansas City, KS, ⁶University of Pisa, Pisa, Italy
Background/Purpose: Dazodalibep (DAZ) is a non-antibody fusion protein that acts as a CD40L antagonist and blocks costimulatory signals between immune cells, including T cells, B…
Abstract Number: 1742 • ACR Convergence 2023
Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA
Rachna Talluri¹, Sudeshna Sen², Timothy Wilson³, Adam Savage⁴, Mark Gillespie⁴, Tom Bumol⁴, Marie Feser¹, Jill Norri⁵, Michael Holer¹, kevin Deane¹, Paul Thompson² and Kristen Demoruelle¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Massachusetts Chan Medical School, Worcester, MA, ³Thomas Jefferson University, Philadelphia, PA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Denver, CO
Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
Abstract Number: 1646 • ACR Convergence 2023
The Real-World Experience of Combined Cranial and Large Vessel FDG-PET/CT in the Investigation of Giant Cell Arteritis
Keren Port¹, Ivan Ho Shon¹, Sally Ayesa¹, Rachel Langford¹, Olivia Bennett¹, Andrew Csillag¹, Stacey Fredericks¹, Luz Palacios-Derflingher², Eva Wegner¹ and Anthony Sammel¹, ¹The Prince of Wales Hospital, Sydney, Australia, ²University of New South Wales, Sydney, Australia
Background/Purpose: GCA is a systemic medium-large vessel vasculitis (M-LVV) involving the cranial arteries, aorta and its major branches. Recent studies have shown that PET/CT including…
Abstract Number: 1250 • ACR Convergence 2023
Local Inflammatory Response Mediated by the Homing of Tfh17 Cells Is Involved in Tissue Injury of Immunoglobulin a Vasculitis
Xiaoxue Ma, Qinglian Jiang and Xuyang Chi, The First Hospital of China Medical University, Shenyang, China
Background/Purpose: Immunoglobulin A vasculitis (IgAV), also named Henoch–Schönlein purpura, is a systemic vasculitis characterized by the deposition of IgA1-dominant immune complexes in small vessels that…
Abstract Number: 1262 • ACR Convergence 2023
“Somebody Who’s Been There and Can Understand the Challenges That You’re Going Through”: Participant Perspectives of a Resilience-Based Energy Management Online Intervention for Systemic Sclerosis with Peer Health Coaches
Yen Chen¹, Alexandra Harper², Tiffany Phanhdone³, Mary Alore¹, Sheri Hicks¹, Adam Pape¹, Gina Jay¹, Shannen Bolde¹, Jennie Feldpausch¹, Dinesh Khanna¹ and Susan Murphy⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ypsilanti Charter Twp, MI, ³Northwestern University, Chicago, IL, ⁴University of Michigan, Plymouth, MI
Background/Purpose: People with systemic sclerosis (SSc) often experience fatigue, which impacts daily life functioning and quality of life. We developed a 12-week, resilience-based energy management…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].